The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease

(2012) Ingrid Ordás et al.   Clinical Gastroenterology and Hepatology

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

(2012) Shomron Ben–Horin et al.   Clinical Gastroenterology and Hepatology

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

(2012) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

(2012) N. Vande Casteele et al.   Journal of Crohns & Colitis

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Assessing Response and Loss of Response to Biological Therapies in IBD

(2011) Henit Yanai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

(2011) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity

(2010) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

(2010) S. Ben-Horin et al.   GUT

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Predicting the response to infliximab from trough serum levels

(2009) P. Rutgeerts et al.   GUT

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

(2008) Gert Van Assche et al.   GASTROENTEROLOGY

Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease

(2007) Mark A. Ainsworth et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY